Salem Investment Counselors’s Opus Genetics IRD Stock Holding History

Salem Investment Counselors’s Portfolio IRD Stock Details IRD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-10	Closed	–	–	1030
2021 Q2	$0	Buy	+10	New	+$50	﹤0.01%	964

Other funds holding IRD

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Group One Trading Chicago, Illinois $52.2B AUM 104.56% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Salem Investment Counselors's IRD Position: Q3 2021 in Review

Salem Investment Counselors sold out of Opus Genetics (IRD) in Q3 2021, closing a stake of 10 shares.

Salem Investment Counselors first reported a position in IRD in Q2 2021 and held it in 1 quarter. The position peaked at $0 in Q2 2021. 30 funds tracked by Wall St. Rank hold IRD as of Q3 2021.

Salem Investment Counselors reported no remaining Opus Genetics position as of Q3 2021 after selling out during the quarter.
Salem Investment Counselors sold 10 Opus Genetics shares in Q3 2021.
Salem Investment Counselors first reported a position in Opus Genetics in Q2 2021 and held it in 1 quarter.
Salem Investment Counselors's Opus Genetics position peaked at $0 in Q2 2021.
30 funds tracked by Wall St. Rank held Opus Genetics as of Q3 2021.

Based on Salem Investment Counselors's 13F filing for Q3 2021, filed 15 Nov 2021.